"Neurology & Psychiatry Should be Treating the Same Organ"
Alice Weaver Flahery
Psychedelics Can Affect Both
Neurology & Psychiatry are interconnected
"Neuralgic pain cannot be “embraced”, fought against or accommodated. It crushes one into a quivering, almost mindless sort of pulp; all one’s powers of will, one’s very identity, disappear under the assault of such pain"
Prof. Oliver Sacks
Neurological disorders are one of the fastest growing set of clinical indications due to large aging populations, lifestyle illnesses and environmental challenges
We focus on neurological indications that are unmet needs with highest interconnection to psychiatry.
Chronic
Pain
Affect 20% of the US population
Chronic
Fatigue
US annual cost of between 18-24B$
Cognitive Impairment
12 Million patients
growing 6X by 2024
Current neurological therapies are stagnant with no major new innovation for years. Regulators and the medical community are seeking novel non addictive solutions. Previous pandemics resulted in a surge of brain health disorders hans Covid-19 has exacerbated the brain health crisis.
Psychedelics are a new, brain targeted class of drugs. Psychedelics reset areas of functional connectivity in the brain, enabling safer, non-addictive solutions for neurology indications affecting large populations with high unmet needs.
We Take Pride in Our History
IMIO is proud to be part of the Nextar \ Nextage Family. Our group brings together years of excellence in innovative pharmaceutical R&D. From synthesis through innovative formulation, analytics and GMP manufacturing, we leverage on decades of experience and in house capabilities
14
Years of Experience
150
Innovative Formulations
40
Scientist and clinical researchers
2000
projects
Our Partners
